Nuala Peter

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

Sam Schulman, Ajay K. Kakkar, Samuel Z. Goldhaber et al. · Circulation · 2013 · 932 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Stanley Cohen, A. Alonso-Ruiz, Piotr Adrian Klimiuk et al. · Annals of the Rheumatic Diseases · 2018 · 112 citations · Full text

Life Sciences, Clinical Sciences, Immunology +11

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition

Yuliya Lytvyn, Karen Kimura, Nuala Peter et al. · Circulation · 2022 · 65 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Sam Schulman, Henry Eriksson, Samuel Z. Goldhaber et al. · Blood · 2013 · 40 citations

Medicine, Pharmacology, Pharmacotherapy +14

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

Stanley Cohen, Niklas Czeloth, Eric Lee et al. · Expert Opinion on Biological Therapy · 2019 · 24 citations · Full text

Medicine, Immunology, Pharmacology +17